Evidence map›Paper›PMID 34977904›Full record

ArticleJACS Au2021

Synthesis and Pharmacological Characterization of Visabron, a Backbone Cyclic Peptide Dual Antagonist of α4β1 (VLA-4)/α9β1 Integrin for Therapy of Multiple Sclerosis.

Chaim Gilon, Michal Klazas, Adi Lahiani, Adi Schumacher-Klinger, Shira Merzbach, Johnny N Naoum, Haim Ovadia, Limor Rubin, Susan Cornell-Kennon, Erik M Schaefer and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACS Au, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Chaim GilonInstitute of Chemistry, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.
Michal KlazasPharmacy, Pharmacology, and Medicinal Chemistry, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112102, Israel.
Adi LahianiPharmacy, Pharmacology, and Medicinal Chemistry, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112102, Israel.
Adi Schumacher-KlingerPharmacy, Pharmacology, and Medicinal Chemistry, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112102, Israel.
Shira MerzbachPharmacy, Pharmacology, and Medicinal Chemistry, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112102, Israel.
Johnny N NaoumInstitute of Chemistry, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.
Haim OvadiaNeurology and Allergy and Clinical Immunology Unit, Hadassah-Hebrew University Medical Center, Jerusalem 9112001, Israel.
Limor RubinNeurology and Allergy and Clinical Immunology Unit, Hadassah-Hebrew University Medical Center, Jerusalem 9112001, Israel.
Susan Cornell-KennonAssayQuant Technologies, Inc., 260 Cedar Hill Street, Marlboro, Massachusetts 01752, United States.
Erik M SchaeferAssayQuant Technologies, Inc., 260 Cedar Hill Street, Marlboro, Massachusetts 01752, United States.
Jehoshua KatzhendlerPharmacy, Pharmacology, and Medicinal Chemistry, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112102, Israel.
Cezary MarcinkiewiczDepartment of Bioengineering, College of Engineering, Temple University, Philadelphia, Pennsylvania 19122, United States.
Amnon HoffmanPharmacy, Pharmacology, and Medicinal Chemistry, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112102, Israel.ORCID https://orcid.org/0000-0002-3848-4093
Philip LazaroviciPharmacy, Pharmacology, and Medicinal Chemistry, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112102, Israel.ORCID https://orcid.org/0000-0003-3650-4721
Hebrew University of Jerusalem · ILHadassah Medical Center · ILTemple University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Integrins α4β1/ α9β1 are important in the pathogenesis and progression of inflammatory and autoimmune diseases by their roles in leukocyte activation and trafficking. Natalizumab, a monoclonal antibody selectively targeting α4β1 integrin and blocking leukocyte trafficking to the central nervous system, is an immunotherapy for multiple sclerosis (MS). However, due to its adverse effects associated with chronic treatment, alternative strategies using small peptide mimetic inhibitors are being sought. In the present study, we synthesized and characterized visabron

Identifiers

PMID34977904
PMCPMC8717366
OpenAlexW3217760893

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.